Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Buying opportunity - Market maker out of business -- Ignore unavailable to you. Want to Upgrade?

To: Master (Hijacked) who wrote (285)	2/17/1998 9:40:00 PM
From: pressboxjr	Respond to of 472

Doug, Thanks for the input. As per the usual, you and "RNTK worm" are right on top of things. Don't know if you saw it, but they did file a 10QSB today. Looking forward to the rest of the week and next. HR

To: Master (Hijacked) who wrote (285)	2/18/1998 9:50:00 AM
From: pressboxjr	Read Replies (1) \| Respond to of 472

Doug, After a fairly quiet day yesterday, RNTK is active this morning! HR

To: Master (Hijacked) who wrote (285)	2/18/1998 10:44:00 AM
From: Mike J	Respond to of 472

FLEM News Release! Wednesday February 18, 10:06 am Eastern Time Company Press Release Flemington Pharmaceutical Announces Agreement With Altana FLEMINGTON, N.J.--(BUSINESS WIRE)--February 18, 1998--Flemington Pharmaceutical Corporation (''Flemington'' or the ''Company'')(OTCBB:''FLEM'') today announced that it has entered into an Agreement with Altana, Inc. of Melville, N.Y. (''Altana''), for the development and marketing of a topical ointment product for the treatment, and immediate relief from the effects, of acute poison ivy inflammation (the ''Product''). Flemington has a patent application pending for the Product. Under the terms of the Agreement, Flemington will conduct a small pilot study, at Flemington's expense, to validate the efficacy of the Product. This pilot study should be completed during the summer of 1998. If Altana is satisfied with the results of the pilot study, Flemington will proceed to conduct clinical trials and file a New Drug Application (NDA) with the United States Food and Drug Administration (FDA) seeking approval for the Product. The clinical trials and the filing of the NDA will be carried out by Flemington and will be funded by Altana. Upon authorizing the project to proceed, Altana will begin making milestone payments to Flemington, plus, following FDA approval of the Product, paying a royalty on Altana's sales. Altana is the United States subsidiary of Altana, AG, a world-wide pharmaceutical company headquartered in Germany. Altana specializes in the manufacture and marketing of topical pharmaceutical and over-the-counter products, including its Savage(R) and Fougera(R) brands. Flemington is engaged in the development of novel application drug delivery systems for presently marketed prescription and over-the-counter drugs. The novel delivery systems include lingual sprays and soft gelatin bite capsules. The company believes that these delivery systems offer (i) improved drug safety by reducing the required dosage, therefore, reducing side effects (ii) improved dosage reliability; (iii) improved patient convenience and compliance; and (iv) enhanced dosage reliability. The company plans to develop such products through collaborate arrangements with major pharmaceutical companies. For further information, contact Robert F. Schaul, Esq., the company's General Counsel, at 908/782-3431.

To: Master (Hijacked) who wrote (285)	2/18/1998 10:58:00 AM
From: Mike J	Read Replies (1) \| Respond to of 472

My Response to FLEM news: It is a very positive release since they previously had no mention of business outside consulting (which will eventually die) and their pill delivery system (which is yet to have a customer). Also, this shows a true commitment to new business ventures outside of consulting. Finally, it show that the doctors at FPC are multi-talented and very able to create real pharmaceutical products. Of course, the negative was that they are financing the testing themselves. But, that's why they have investors like us.... MikeJ